Neuromuscular

The Abbott system previously earned approval for chronic pain in 2019, and adds another option for a patient population with no disease-modifying agents available for treatment.

Drs Juliana Gurgel Giannetti, Adriana Banzzatto Ortega and Marcelo Kerstenetzky discuss symptoms of spinal muscular atrophy and diagnosis and referral process in Brazil. / Drs Juliana Gurgel Giannetti, Adriana Banzzatto Ortega e Marcelo Kerstenetzky discutem sintomas da atrofia muscular espinhal, diagnóstico e processo de encaminhamento no Brasil.

Dr Rodrigo de Holanda Mendonça provides an overview of spinal muscular atrophy (SMA). / Dr Rodrigo de Holanda Mendonça dá uma visão geral sobre Atrofia Muscular Espinhal (AME).

Ahead of the 2023 MDA Conference, which will be held from March 19-22, 2023, in Dallas, Texas, the vice president of public policy and advocacy at the Muscular Dystrophy Association provided an overview of the current state of access and the need for more advocates in neuromuscular disease. [WATCH TIME: 14 minutes]

Similar to results at 24-months, findings showed improvements in patient outcomes with the SCS System including quality of life, functional ability, mood, and sleep.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is genetic neurological disorders.

After a 12-month period, patients were able to use the implant for routine digital activities, such as texting, emailing, personal finance, online shopping, and communication of care needs.

The FDA lifted its clinical hold on Astellas Pharma's FORTIS trial for evaluating AT845 in adults with late-onset Pompe disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 20, 2023.

Nearly 94% of nusinersen doses recorded in electronic health records database and more than 80% of doses recorded in the claims databases were received on time according to the recommended dosing schedule.

Sacco, who also served as president of the American Heart Association/ American Stroke Association, succumbed to a brain tumor on January 17, 2023.

The executive director of Cure CMD provided perspective on a new 10-month program that aims to align patient and clinician perspectives on certain rare neuromuscular disorders.

James F. Howard Jr, MD, and Nicholas J. Silvestri, MD, FAAN, offer their experiences in treating patients with myasthenia gravis and their thoughts on the future of the care paradigm with novel agents in development.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

The neurosurgeon at Allegheny Health Network detailed the potential for robotics in neurosurgery over the coming years, and the vast improvements in comfortability during these procedures. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 13, 2023.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sarah Boyce. [LISTEN TIME: 21 minutes]

The neurosurgeon at Allegheny Health Network provided background on a new, state-of-the-art tool designed to ultimately improve neurosurgical procedures. [WATCH TIME: 3 minutes]

The virtual care program built by The Ohio State University Wexner Medical Center allows for expanded access to patient care in rural areas, improved decision-making, and hands-on experience for young neurologists.

Angela Lek, PhD, and Tahseen Mozaffar, MD, offered their insight into myositis and the clinical needs for the population, ahead of a focused session on it, chaired by Mozzafar at the MDA’s Clinical & Scientific Conference.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 6, 2023.

UCB’s rozanolixizumab received priority review on its biologic license application by FDA and expects feedback during the second quarter of 2023.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network for the week ending December 31, 2022. [WATCH TIME: 3 minutes]

In 2022, these episodes of the Mind Moments® podcast got the most attention from listeners, with this list brought to you as part of NeurologyLive®'s Year in Review.

These were the most-watched interviews with experts in neuromuscular disorders that we conducted in 2022, brought to you as part of NeurologyLive®'s Year in Review.